A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 1015
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : hERG
Long Form : human ether-a-go-go-related gene
No. Year Title Co-occurring Abbreviation
2023 Antimalarial activity assay of artesunate-3-chloro-4(4-chlorophenoxy) aniline in vitro and in mice models. 4DTs, ADMET, ANOVA, ATS, ATSA, ED50, HIA, IC50, LuR, OECD, PQR, TI
2023 Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment. BBB, EPS, MD, TAAR1
2023 Deciphering HERG mutation in long QT syndrome type 2 using antisense oligonucleotide-mediated techniques: Lessons from cystic fibrosis. ASO, CF, LQT2, mRNA
2023 DNA topoisomerase 2-associated proteins PATL1 and PATL2 regulate the biogenesis of hERG K+ channels. hiPSC-CMs
2023 Elucidation of ALG10B as a Novel Long-QT Syndrome-Susceptibility Gene. ALG10B, LQTS
2023 Ensemble of structure and ligand-based classification models for hERG liability profiling. LB, SB
2023 Enzastaurin cardiotoxicity: QT interval prolongation, negative inotropic responses and negative chronotropic action. APD, ECG, RyR2, SERCA2a
2023 Evaluation of Some Safety Parameters of Dual Histamine H3 and Sigma-2 Receptor Ligands with Anti-Obesity Potential. ALAT, G-GT
2023 hERG Blockade Prediction by Combining Site Identification by Ligand Competitive Saturation and Physicochemical Properties. cryo-EM, QSAR, SILCS
10  2023 High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers. CSFs, ECM
11  2023 Importance of modelling hERG binding in predicting drug-induced action potential prolongations for drug safety assessment. ---
12  2023 In silico mechanisms of arsenic trioxide-induced cardiotoxicity. APL, ATO, ENDO, EPI, MCELL, VMs
13  2023 In silico prediction of hERG blockers using machine learning and deep learning approaches. GCNs, ML
14  2023 Integrated analysis of the voltage-gated potassium channel-associated gene KCNH2 across cancers. GBM
15  2023 Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat. ECG
16  2023 Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature. LAAM
17  2023 Sophoridine manifests as a leading compound for anti-arrhythmia with multiple ion-channel blocking effects. APD90, CiPA, CV, EAD, HR, hSCCMs, ISO, LCAL, MEA, PES, SR, VT
18  2022 A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo. ---
19  2022 A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects. PDE10A
20  2022 Automatic modeling of dynamic drug-hERG channel interactions using three voltage protocols and machine learning techniques: A simulation study. ---
21  2022 BayeshERG: a robust, reliable and interpretable deep learning model for predicting hERG channel blockers. ---
22  2022 Biphenyl scaffold for the design of NMDA-receptor negative modulators: molecular modeling, synthesis, and biological activity. NAM, NMDA
23  2022 Cardiac Electropharmacological Effects of Antidiarrheal Drug Loperamide and Its Antidote Naloxone in Anesthetized Guinea Pigs. ECG, MAP
24  2022 Cell-Based hERG Channel Inhibition Assay in High-Throughput Format. ---
25  2022 Design, synthesis and biological activity evaluation of a series of bardoxolone methyl prodrugs. CTSB, CUK, DN, PEG
26  2022 Discovery of 2-vinyl-10H-phenothiazine derivatives as a class of ferroptosis inhibitors with minimal human Ether-a-go-go related gene (hERG) activity for the treatment of DOX-induced cardiomyopathy. SAR
27  2022 Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity. FGFR3
28  2022 Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. hiPSC-CMs, SGK1
29  2022 Establishment of human embryonic stem cell WAe009-A-74 carrying a Long QT syndrome mutation in KCNH2. LQT2
30  2022 HergSPred: Accurate Classification of hERG Blockers/Nonblockers with Machine-Learning Models. LQTS
31  2022 High-Throughput Chemical Screening and Structure-Based Models to Predict hERG Inhibition. CV, NCATS, qHTS
32  2022 Identification and New Indication of Melanin-Concentrating Hormone Receptor 1 (MCHR1) Antagonist Derived from Machine Learning and Transcriptome-Based Drug Repositioning Approaches. LDLR, MCHR1, NASH
33  2022 Identification of novel bioactive compounds from Olea europaea by evaluation of chemical compounds in the OliveNet™ library: in silico bioactivity and molecular modelling, and in vitro validation of hERG activity. P-gp, SMD
34  2022 In-situ and amplification-free imaging of hERG ion channels at single-cell level using a unique core-molecule-shell-secondary antibody SERS nanoprobe. SERS
35  2022 Inhibition of human ether-a-go-go-related gene K+ currents expressed in HEK293 cells by three gingerol components from ginger. ---
36  2022 Investigating cardiotoxicity related with hERG channel blockers using molecular fingerprints and graph attention mechanism. ---
37  2022 Investigational New Drug Enabling Nonclinical Safety Pharmacology Assessment of the Iminosugar UV-4, a Broad-Spectrum Host-Targeted Antiviral Agent. CNS, IND
38  2022 Ion channel model reduction using manifold boundaries. MBAM
39  2022 Lead optimization of pyrido[2,3-d][1]benzazepin-6-one derivatives leading to the discovery of a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) antagonist (DS69910557). hPTHR1
40  2022 Ligand-based prediction of hERG-mediated cardiotoxicity based on the integration of different machine learning techniques. SMOTE
41  2022 Loperamide-Induced Torsades de Pointes. ---
42  2022 Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome. diLQTS, TdP
43  2022 Molecular Determinants for the High-Affinity Blockade of Human Ether-à-go-go-Related Gene K + Channel by Tolterodine. ---
44  2022 Mutagenicity and safety pharmacology of a standardized antidiabetic polyherbal formulation. DRF, FOB, MN
45  2022 Pharmacological characterisation of electrocardiogram J-Tpeak interval in conscious Guinea pigs. QT, TdP
46  2022 Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy. Ang II, PCH
47  2022 Pore opening, not voltage sensor movement, underpins the voltage-dependence of facilitation by a hERG blocker. ---
48  2022 Predicting hERG channel blockers with directed message passing neural networks. D-MPNN
49  2022 Repurposing drugs as COVID-19 therapies: A toxicity evaluation. CPE, PLD, SARS-CoV-2
50  2022 Structural Alterations of the "Address" Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity. ---
51  2022 Structural modeling of the hERG potassium channel and associated drug interactions. ---
52  2022 Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics. ---
53  2022 The grapefruit polyphenol naringenin inhibits multiple cardiac ion channels. AP, CiPA, ECG
54  2022 The Linkage Phase of the Polymorphism KCNH2-K897T Influences the Electrophysiological Phenotype in hiPSC Models of LQT2. hiPSC-CMs, hiPSCs, LQT2, SNP
55  2022 Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays. siRNA
56  2022 Use of Solvent Mapping for Characterizing the Binding Site and for Predicting the Inhibition of the Human Ether-á-Go-Go-Related K+ Channel. ---
57  2022 Vicious LQT induced by a combination of factors different from hERG inhibition. APD, EADs, ECG, LQT, TdP, VF
58  2021 2-((2-(4-Iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol (25I-NBOH) and 2-(((2-(4-chloro-2,5-dimethoxyphenyl)ethyl)amino)methyl)phenol (25C-NBOH) induce adverse effects on the cardiovascular system. ECG, LVDP, NPSs, PAK1
59  2021 A Phase 1 Study to Investigate the Effects of Cortexolone 17alpha-Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity. ---
60  2021 Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers. CI, QTcF
61  2021 Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome. AD, LQTS, TdP
62  2021 Association between the serum concentrations and mutational status of IL-8, IL-27 and VEGF and the expression levels of the hERG potassium channel gene in patients with colorectal cancer. CRC
63  2021 Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action. AMPK, mTOR, PCSK9
64  2021 Cardiotoxicity assessment using 3D vascularized cardiac tissue consisting of human iPSC-derived cardiomyocytes and fibroblasts. ADD, hiPSC-CMs, MCS
65  2021 Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. FQs, HCQ, SAES-CoV-2
66  2021 COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. LQTS
67  2021 Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor. KRAS, MAPK, NF-1, PK, RTK, SH2
68  2021 Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect. DA
69  2021 Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives. GPR119
70  2021 Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach. HBA
71  2021 Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. EZH2, SAR
72  2021 Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities. MIC
73  2021 Disruption of protein quality control of the human ether-a-go-go related gene K+ channel results in profound long QT syndrome. hiPSC-CMs, LQTS, RNF207
74  2021 Dual Mechanisms of Cardiac Action Potential Prolongation by 4-Oxo-Nonenal Increasing the Risk of Arrhythmia; Late Na+ Current Induction and hERG K+ Channel Inhibition. 4-HNE, 4-ONE, APD, INaL
75  2021 Flavonoids and hERG channels: Friends or foes? ---
76  2021 Ginsenoside Rg3 Alleviates Antithyroid Cancer Drug Vandetanib-Induced QT Interval Prolongation. ECG, hiPSC-CMs, MAP
77  2021 hERG-deficient human embryonic stem cell-derived cardiomyocytes for modelling QT prolongation. CM, hESC, LQT2, MEA
78  2021 Induced Pluripotent Stem Cell-Derived Cardiomyocytes with SCN5A R1623Q Mutation Associated with Severe Long QT Syndrome in Fetuses and Neonates Recapitulates Pathophysiological Phenotypes. CM, EAD, iPSC, LQT3
79  2021 Investigation of PAS and CNBH domain interactions in hERG channels and effects of long-QT syndrome-causing mutations with surface plasmon resonance. CNBH, LQTS, PAS, SPR
80  2021 L51P, a novel mutation in the PAS domain of hERG channel, confers long QT syndrome by impairing channel activation. LQTS, MD, PAS, PME
81  2021 Mechanisms of gefitinib-induced QT prolongation. APD, NSCLC
82  2021 Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity. NCEs
83  2021 Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva. ALK2, BMP
84  2021 Parallel Recordings of Transmembrane hERG Channel Currents Based on Solvent-Free Lipid Bilayer Microarray. BLMs, Si
85  2021 Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation. COVID-19, SARS-CoV-2
86  2021 Pharmacological corrections of the mutant hERG channels by posaconazole. HEK, WT
87  2021 Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis. 5-HT, AEs
88  2021 Proarrhythmic effects induced by benzethonium chloride and domiphen bromide in vitro and in vivo. BZT, DMP, hiPSC-CMs
89  2021 Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity. ---
90  2021 Refinement of a cryo-EM structure of hERG: Bridging structure and function. MDFF, VSD
91  2021 Role and mechanism of chaperones calreticulin and ERP57 in restoring trafficking to mutant HERG‑A561V protein. CNX, CRT, ERP57, WT
92  2021 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. CNS
93  2021 Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth. TB
94  2021 Structure-Based Prediction of hERG-Related Cardiotoxicity: A Benchmark Study. IFs, SVM
95  2021 The Effect of a Synthetic Estrogen, Ethinylestradiol, on the hERG Block by E-4031. ---
96  2021 TSSF-hERG: A machine-learning-based hERG potassium channel-specific scoring function for chemical cardiotoxicity prediction. RMSE, rs, SVR
97  2020 AKAP5 anchors PKA to enhance regulation of the HERG channel. AKAPs, beta-AR, LQTS, PKA
98  2020 Assessment of spatial heterogeneity of ventricular repolarization after multi-channel blocker drugs in healthy subjects. SHVR
99  2020 Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase. hAMCase
100  2020 Critical Assessment of Artificial Intelligence Methods for Prediction of hERG Channel Inhibition in the "Big Data" Era. AI, DNNs, RNNs